GASC
MCID: GST053
MIFTS: 78

Gastric Cancer (GASC)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Gastric Cancer

MalaCards integrated aliases for Gastric Cancer:

Name: Gastric Cancer 58 39 12 54 76 38 56 15
Stomach Cancer 12 77 54 76 30 44 15
Stomach Carcinoma 12 54 15 74
Gastric Carcinoma 12 56 15 17
Malignant Tumor of Lesser Curve of Stomach 12 74
Malignant Neoplasm of Body of Stomach 12 74
Stomach Neoplasms 45 74
Malignant Neoplasm of Lesser Curve of Stomach 12
Malignant Tumor of Greater Curve of Stomach 12
Malignant Tumor of Body of Stomach 12
Ca Greater Curvature of Stomach 12
Ca Lesser Curvature - Stomach 12
Malignant Neoplasm of Stomach 74
Gastric Cancer Intestinal 76
Gastric Cancer, Somatic 58
Adult Stomach Carcinoma 54
Cancer of the Stomach 12
Carcinoma of Stomach 12
Adult Stomach Cancer 54
Ca Body - Stomach 12
Gastric Neoplasm 12
Stomach Neoplasm 17
Cancer, Gastric 41
Gasc 76

Characteristics:

HPO:

33
gastric cancer:
Inheritance somatic mutation


Classifications:



Summaries for Gastric Cancer

NIH Rare Diseases : 54 Stomach cancer, also called gastric cancer, is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the stomach. Most people with early stomach cancer have no signs or symptoms of the condition. In advanced stages, symptoms may include indigestion; nausea and vomiting; difficulty swallowing; feeling full after eating small amounts of food; loss of appetite; vomiting blood; fatigue; and/or weight loss. Most cases of stomach cancer occur sporadically in people with little to no family history of the condition; however, approximately 10% of stomach cancers are considered "familial." Although the underlying cause of some familial cases is unknown, genetic changes (mutations) are identified in a subset of people affected by stomach cancer. Hereditary cancer syndromes associated with a predisposition to stomach cancer include hereditary diffuse gastric cancer, Lynch syndrome, Li-Fraumeni syndrome, familial adenomatous polyposis, and Peutz-Jeghers syndrome. In other families, a cluster of stomach cancers may be due to a combination of gene(s) and/or other shared factors such as environment and lifestyle. The best treatment options for stomach cancer depend on many factors including the stage of the condition and may include surgery, chemotherapy, radiation therapy, and/or targeted therapy (such as monoclonal antibody therapy).

MalaCards based summary : Gastric Cancer, also known as stomach cancer, is related to gastric adenocarcinoma and colorectal cancer, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Gastric Cancer is APC (APC Regulator Of WNT Signaling Pathway), and among its related pathways/superpathways are Gastric cancer and PI3K-Akt signaling pathway. The drugs Cyramza and Herceptin have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and lung, and related phenotypes are stomach cancer and increased level of l-fucose in urine

Disease Ontology : 12 A gastrointestinal system cancer that is located in the stomach.

OMIM : 58 In a review article on the genetic predisposition to gastric cancer, Bevan and Houlston (1999) concluded that several genes may be associated with an increased risk of gastric cancer. Gastric cancer is a manifestation of a number of inherited cancer predisposition syndromes, including hereditary nonpolyposis colon cancer (HNPCC1; see 120435), familial adenomatous polyposis (FAP; 175100), Peutz-Jeghers syndrome (PJS; 175200), Cowden disease (CD; 158350), and the Li-Fraumeni syndrome (151623). See also hereditary diffuse gastric cancer (HDGC; 137215). Canedo et al. (2007) provided a review of genetic susceptibility to gastric cancer in patients infected with Helicobacter pylori (see 600263). (613659)

MedlinePlus : 44 The stomach is an organ between the esophagus and the small intestine. It mixes food with stomach acid and helps digest protein. Stomach cancer mostly affects older people - two-thirds of people who have it are over age 65. Your risk of getting it is also higher if you Have had a Helicobacter pylori infection Have had stomach inflammation Are a man Eat lots of salted, smoked, or pickled foods Smoke cigarettes Have a family history of stomach cancer It is hard to diagnose stomach cancer in its early stages. Indigestion and stomach discomfort can be symptoms of early cancer, but other problems can cause the same symptoms. In advanced cases, there may be blood in your stool, vomiting, unexplained weight loss, jaundice, or trouble swallowing. Doctors diagnose stomach cancer with a physical exam, blood and imaging tests, an endoscopy, and a biopsy. Because it is often found late, it can be hard to treat stomach cancer. Treatment options include surgery, chemotherapy, radiation or a combination. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Gastric cancer: A malignant disease which starts in the stomach, can spread to the esophagus or the small intestine, and can extend through the stomach wall to nearby lymph nodes and organs. It also can metastasize to other parts of the body. The term gastric cancer or gastric carcinoma refers to adenocarcinoma of the stomach that accounts for most of all gastric malignant tumors. Two main histologic types are recognized, diffuse type and intestinal type carcinomas. Diffuse tumors are poorly differentiated infiltrating lesions, resulting in thickening of the stomach. In contrast, intestinal tumors are usually exophytic, often ulcerating, and associated with intestinal metaplasia of the stomach, most often observed in sporadic disease.

Wikipedia : 77 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Related Diseases for Gastric Cancer

Diseases related to Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 679)
# Related Disease Score Top Affiliating Genes
1 gastric adenocarcinoma 33.7 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
2 colorectal cancer 32.5 APC CTNNB1 ERBB2 KRAS MIR106B MIR141
3 adenocarcinoma 32.4 APC CTNNB1 ERBB2 FGFR2 KRAS PIK3CA
4 breast cancer 32.4 APC CTNNB1 ERBB2 FGFR2 KRAS MIR141
5 prostate cancer 32.0 CTNNB1 ERBB2 FGFR2 KLF6 KRAS MIR106B
6 hepatocellular carcinoma 31.9 APC CTNNB1 KRAS MIR106B MIR141 MIR145
7 esophageal cancer 31.9 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR34A
8 lung cancer 31.9 ERBB2 FGFR2 IRF1 KRAS MIR141 MIR145
9 adenoma 31.8 APC CTNNB1 KRAS MUTYH
10 pancreatic cancer 31.6 CTNNB1 ERBB2 KRAS MIR203A MIR21 MIR221
11 familial adenomatous polyposis 31.6 APC CTNNB1 KRAS MUTYH
12 melanoma 31.4 MIR141 MIR200C MIR221 MIR27A MIR34A
13 cholangiocarcinoma 31.4 CTNNB1 ERBB2 KRAS MIR141 MIR21 PIK3CA
14 lynch syndrome 31.4 APC CTNNB1 KRAS MUTYH
15 large intestine cancer 31.3 APC CTNNB1 ERBB2 KRAS MUTYH PIK3CA
16 lung cancer susceptibility 3 31.3 APC CTNNB1 ERBB2 KLF6 KRAS PIK3CA
17 bladder cancer 31.2 ERBB2 KRAS MIR145 MIR203A MIR21 MIR221
18 cervical cancer 31.1 CTNNB1 ERBB2 IRF1 MIR21 PIK3CA
19 ovarian cancer 31.1 CTNNB1 ERBB2 KRAS MIR106B MIR141 MIR145
20 glioma 31.1 ERBB2 MIR21 MIR221 MIR25 MIR34A PIK3CA
21 endometrial cancer 31.0 CTNNB1 ERBB2 FGFR2 KRAS MIR200C MUTYH
22 respiratory system cancer 30.9 CTNNB1 ERBB2 KRAS PIK3CA
23 adenoid cystic carcinoma 30.8 CTNNB1 ERBB2 KRAS PIK3CA
24 intrahepatic cholangiocarcinoma 30.8 CTNNB1 FGFR2 KRAS
25 colorectal adenoma 30.8 APC CTNNB1 KRAS MUTYH
26 intestinal disease 30.8 CTNNB1 KRAS MUTYH PIK3CA
27 medulloblastoma 30.8 APC CTNNB1 ERBB2 MIR34A PIK3CA
28 nonalcoholic fatty liver disease 30.8 MIR200C MIR203A MIR21 MIR27A MIR34A
29 kidney cancer 30.8 MIR106B MIR141 MIR200C MIR21 MIR27A
30 pancreatic ductal adenocarcinoma 30.8 MIR141 MIR145 MIR203A MIR21 MIR221
31 leukemia, chronic lymphocytic 2 30.7 KRAS MIR106B MIR145 MIR34A
32 ovarian cancer 1 30.7 ERBB2 KRAS PIK3CA
33 desmoid disease, hereditary 30.6 APC CTNNB1
34 desmoid tumor 30.5 APC CTNNB1
35 attenuated familial adenomatous polyposis 30.4 APC MUTYH
36 gastric cancer, hereditary diffuse 12.8
37 diffuse gastric cancer 12.6
38 microinvasive gastric cancer 12.5
39 stomach carcinoma in situ 12.4
40 epstein-barr virus-associated gastric carcinoma 12.3
41 carcinoma of stomach, salivary gland type 12.2
42 undifferentiated carcinoma of stomach 12.2
43 gastric adenocarcinoma and proximal polyposis of the stomach 11.4
44 li-fraumeni syndrome 11.4
45 li-fraumeni syndrome 2 11.4
46 gastric squamous cell carcinoma 11.1
47 gastric adenosquamous carcinoma 11.1
48 gastric small cell carcinoma 11.1
49 stomach cancer, childhood 11.1
50 gastric linitis plastica 11.1

Comorbidity relations with Gastric Cancer via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Gastric Fundus Cancer
Heart Disease Intestinal Obstruction
Iron Deficiency Anemia Neutropenia
Protein-Energy Malnutrition Pylorus Cancer
Stomach Carcinoma in Situ

Graphical network of the top 20 diseases related to Gastric Cancer:



Diseases related to Gastric Cancer

Symptoms & Phenotypes for Gastric Cancer

Human phenotypes related to Gastric Cancer:

33
# Description HPO Frequency HPO Source Accession
1 stomach cancer 33 HP:0012126
2 increased level of l-fucose in urine 33 HP:0410067

Clinical features from OMIM:

613659

UMLS symptoms related to Gastric Cancer:


nausea and vomiting, constipation, abdominal pain, diarrhea, icterus, dyspepsia, heartburn, gastrointestinal gas

MGI Mouse Phenotypes related to Gastric Cancer:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 APC CTNNB1 ERBB2 FGFR2 IRF1 KLF6
2 neoplasm MP:0002006 9.23 APC CTNNB1 ERBB2 FGFR2 IRF1 KRAS

Drugs & Therapeutics for Gastric Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Cyramza 19 50 RAMUCIRUMAB Eli Lilly April 2014
2
Herceptin 19 50 TRASTUZUMAB Genentech October 1998
3
Iressa 19 50 GEFITINIB AstraZeneca May 2003

Drugs for Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 591)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 100286-90-6, 97682-44-5 60838
2
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 154361-50-9 60953
3
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
5
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
6
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
7
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 100986-85-4 149096
8
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81103-11-9 84029
9
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
10
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
11
Ofloxacin Approved Phase 4,Phase 3,Phase 1 82419-36-1 4583
12
Pravastatin Approved Phase 4 81093-37-0 54687
13
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
14
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
15
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
16
Iron isomaltoside 1000 Approved, Investigational Phase 4 1370654-58-2
17
Iron Approved, Experimental Phase 4,Phase 3,Not Applicable 7439-89-6, 15438-31-0 27284 23925
18
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
19
Tetracycline Approved, Vet_approved Phase 4,Phase 3 60-54-8 5353990
20
Metronidazole Approved Phase 4,Phase 3,Phase 1 443-48-1 4173
21
Tinidazole Approved, Investigational Phase 4,Phase 3 19387-91-8 5479
22
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 93-14-1 3516
23
Famotidine Approved Phase 4,Phase 1 76824-35-6 3325
24
Histamine Approved, Investigational Phase 4,Phase 1,Not Applicable 51-45-6 774
25
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
26
Lansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 103577-45-3 3883
27
Dexlansoprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 138530-94-6, 103577-45-3 9578005
28
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 73590-58-6 4594
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
30
Etomidate Approved Phase 4 33125-97-2 667484 36339
31
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
32
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
33
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 5311068 68602
34
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
35
Levoleucovorin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68538-85-2
36
Docetaxel Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 114977-28-5 148124
37
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
38
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
39
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
40
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
41
Floxuridine Approved Phase 4,Phase 3,Phase 2,Phase 1 50-91-9 5790
42
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
43
Simethicone Approved Phase 4 8050-81-5
44
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
45
Morphine Approved, Investigational Phase 4 57-27-2 5288826
46
Coal tar Approved Phase 4 8007-45-2
47
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
48
Dopamine Approved Phase 4,Phase 2 62-31-7, 51-61-6 681
49
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
50
Pasireotide Approved Phase 4,Phase 1 396091-73-9 9941444

Interventional clinical trials:

(show top 50) (show all 1963)
# Name Status NCT ID Phase Drugs
1 Gastrectomy Plus Prophylactic Cholecystectomy in Gastric Cancer Surgery Unknown status NCT00757640 Phase 4
2 A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy Unknown status NCT02776527 Phase 4 Apatinib Mesylate Tablets
3 Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients Unknown status NCT01910948 Phase 4 omega-3 polyunsaturated fatty acids
4 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer Unknown status NCT02401971 Phase 4 Thalidomide;CPT-11
5 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
6 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
7 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
8 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
9 Community-based Helicobacter Pylori Eradication Unknown status NCT00155389 Phase 4 Helicobacter pylori eradication
10 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Unknown status NCT02426034 Phase 4 Apatinib
11 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
12 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
13 Iron Replacement in Oesophagogastric Neoplasia Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
14 A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized,Cross-over Study Unknown status NCT02930616 Phase 4
15 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
16 Effect of Helicobacter Pylori on the Availability of Vitamin E and C Unknown status NCT00303160 Phase 4 vitamin C & E supplements
17 Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment Unknown status NCT03139253 Phase 4 amoxicillin;clarithromycin;tinidazole;levofloxacin;furazolidone;tetracycline;Ilaprazole
18 Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment Unknown status NCT02988089 Phase 4 Clarithromycin susceptibility dependant strategy;2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline );proton pump inhibitor (PPI) and Colloidal Bismuth Pectin;amoxicillin and clarithromycin or amoxicillin and furazolidone;amoxicillin and furazolidone or amoxicillin and tetracycline;amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin
19 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
20 Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia Unknown status NCT00978159 Phase 4 esomeprazole;Famotidine
21 Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
22 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication Unknown status NCT01464060 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
23 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
24 Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
25 Combined Use of Etomidate and Propofol in Painless Gastroscopy. Unknown status NCT01913054 Phase 4 Fentanyl Injection;Etomidate Fat Emulsion Injection;Propofol Injection
26 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
27 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection Completed NCT01914692 Phase 4 Somatostatin
28 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4 mistletoe extract;doxifluridine
29 Efficacy and Safety of CO2 vs Room Air Insufflation During ESD for Gastric Tumor Completed NCT01579071 Phase 4
30 The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study Completed NCT02235246 Phase 4 Magnesium Sulfate;Normal saline
31 Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy Completed NCT01653171 Phase 4 Water (Placebo);Simethicone;N-acetylcysteine 500 mg;N-acetylcysteine 1000 mg
32 Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia Completed NCT01471756 Phase 4
33 Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02458573 Phase 4
34 Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study- Completed NCT01234272 Phase 4 morphine;Ropivacaine
35 The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy Completed NCT02164448 Phase 4 the dexmedetomidine group;the control group
36 Standard and Immunostimulating Enteral Nutrition in Surgical Patients Completed NCT00576940 Phase 4 Reconvan;Peptisorb
37 The Impact of Immunostimulating Nutrition on the Outcome of Surgery Completed NCT00558155 Phase 4 peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
38 Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
39 Oncoxin® and Quality of Life in Cancer Patients Completed NCT03550482 Phase 4
40 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
41 Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03524833 Phase 4 Metronidazole;Lansoprazole, Amoxicillin, Metronidazole
42 Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03521726 Phase 4 Amoxicillin;Rabeprazole, Amoxicillin
43 Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection Completed NCT03516669 Phase 4 Clarithromycin;Amoxicillin, Clarithromycin
44 Intraluminal Therapy for Helicobacter Pylori Infection Completed NCT03124420 Phase 4 Lansoprazole;Amoxicillin;Clarithromycin
45 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
46 The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study Completed NCT00885417 Phase 4 Cravit-based sequential therapy
47 Efficacy of 10-day and 14-day Sequential Therapy Versus Triple Therapy on the Eradication of Helicobacter Pylori Completed NCT01042184 Phase 4 Sequential therapy for 14 days;Sequential therapy for 10 days;Triple therapy for 14 days
48 The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection Completed NCT01032655 Phase 4 susceptibility test guided sequential therapy
49 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
50 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch

Search NIH Clinical Center for Gastric Cancer

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: stomach neoplasms

Genetic Tests for Gastric Cancer

Genetic tests related to Gastric Cancer:

# Genetic test Affiliating Genes
1 Stomach Cancer 30

Anatomical Context for Gastric Cancer

MalaCards organs/tissues related to Gastric Cancer:

42
Lymph Node, Liver, Lung, Breast, Testes, T Cells, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Gastric Cancer:

20
The Stomach

Publications for Gastric Cancer

Articles related to Gastric Cancer:

(show top 50) (show all 16568)
# Title Authors Year
1
New metastatic lymph node classification for early gastric cancer should differ from those for advanced gastric adenocarcinoma: Results based on the SEER database. ( 30705892 )
2019
2
Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer. ( 30069742 )
2019
3
Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. ( 30005807 )
2019
4
Nonhealing gastric ulcer: progression from gastric adenoma to early gastric cancer over 9 years. ( 30176228 )
2019
5
The role of trait emotional intelligence in quality of life, anxiety and depression symptoms after surgery for esophageal or gastric cancer: A French national database FREGAT. ( 30734393 )
2019
6
Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer. ( 30315306 )
2019
7
Correction: Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer. ( 30844907 )
2019
8
Do subjects with mild or moderate atrophic gastritis or intestinal metaplasia confined to the antrum benefit from gastric cancer surveillance? ( 31030192 )
2019
9
Polymorphism in Toll-Like Receptors and Helicobacter Pylori Motility in Autoimmune Atrophic Gastritis and Gastric Cancer. ( 31083432 )
2019
10
A Diagnostically Challenging Case of Autoimmune Pancreatitis Due to Contamination of the Pathological Specimen with Early Gastric Cancer. ( 30626846 )
2019
11
Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis. ( 30626829 )
2019
12
Nivolumab-related Sclerosing Cholangitis in Gastric Cancer. ( 30626840 )
2019
13
Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature. ( 30306390 )
2019
14
Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer. ( 31096937 )
2019
15
Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt? ( 30597479 )
2019
16
Response: patient blood management strategies for iron-deficiency anemia management in gastric cancer. ( 30720606 )
2019
17
Patient Blood Management strategies for iron deficiency anemia management in gastric cancer. ( 30829765 )
2019
18
Gastric cancer and paraneoplastic dermatomyositis as complications of an unrecognized juvenile polyposis syndrome. ( 30873576 )
2019
19
Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. ( 29589180 )
2019
20
Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary diffuse gastric cancer? ( 30466290 )
2019
21
Establishing a center of excellence for hereditary diffuse gastric cancer syndrome. ( 30618047 )
2019
22
Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). ( 30745422 )
2019
23
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. ( 30870726 )
2019
24
INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. ( 30871613 )
2019
25
Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer. ( 30935944 )
2019
26
Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. ( 31058107 )
2019
27
The benefits of a model of interval comprehensive assessments (MICA) in hereditary cancer Syndromes: Hereditary diffuse gastric cancer (HDGC) as an example. ( 31109593 )
2019
28
What Is the Best Operation for Proximal Gastric Cancer and Distal Esophageal Cancer? ( 31047035 )
2019
29
Endoscopic and histologic features associated with gastric cancer in familial adenomatous polyposis. ( 30597145 )
2019
30
Hemi-double stapling technique performed with a transorally inserted anvil for esophagojejunostomy in the surgical treatment of gastric cancer. ( 31099183 )
2019
31
More is not always better: triplet chemotherapy and advanced gastric cancer. ( 31101533 )
2019
32
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial. ( 31101534 )
2019
33
Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer. ( 31102009 )
2019
34
Racial/ethnic differences in survival among gastric cancer patients in california. ( 31102083 )
2019
35
Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway. ( 31102118 )
2019
36
Hypoxic Macrophage-Derived VEGF Promotes Proliferation and Invasion of Gastric Cancer Cells. ( 31102128 )
2019
37
Decreased miR-155-5p, miR-15a, and miR-186 Expression in Gastric Cancer Is Associated with Advanced Tumor Grade and Metastasis ( 31103022 )
2019
38
Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis. ( 31103997 )
2019
39
Using tRNA halves as novel biomarkers for the diagnosis of gastric cancer. ( 31104009 )
2019
40
Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. ( 31104175 )
2019
41
ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/ HMGA1 axis. ( 31104318 )
2019
42
Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells. ( 31105791 )
2019
43
A novel circular RNA hsa_circ_0008035 contributes to gastric cancer tumorigenesis through targeting the miR-375/YBX1 axis. ( 31105852 )
2019
44
Radiomics Signature on Computed Tomography Imaging: Association With Lymph Node Metastasis in Patients With Gastric Cancer. ( 31106158 )
2019
45
Downregulation of microRNA-92b-3p suppresses proliferation, migration, and invasion of gastric cancer SGC-7901 cells by targeting Homeobox D10. ( 31106881 )
2019
46
Elastic Staining on Paraffin-embedded Slides of pT3N0M0 Gastric Cancer Tissue. ( 31107435 )
2019
47
Differential Helicobacter pylori Plasticity in the Gastric Niche of Subjects at Increased Gastric Cancer Risk. ( 31109082 )
2019
48
Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer. ( 31110545 )
2019
49
KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. ( 31111275 )
2019
50
The effect of combined miR-200c replacement and cisplatin on apoptosis induction and inhibition of gastric cancer cell line migration. ( 31111481 )
2019

Variations for Gastric Cancer

UniProtKB/Swiss-Prot genetic disease variations for Gastric Cancer:

76 (show all 19)
# Symbol AA change Variation ID SNP ID
1 APC p.Gly817Cys VAR_005035
2 APC p.Ile880Thr VAR_005036 rs140029598
3 APC p.Asn942Asp VAR_005039
4 APC p.Gly1120Glu VAR_005042 rs28933379
5 APC p.Arg1171His VAR_005043 rs372481703
6 APC p.Phe1197Ser VAR_005045
7 APC p.Ile1259Thr VAR_005046
8 APC p.Gly1312Glu VAR_005050
9 APC p.Val1326Ala VAR_005052
10 CASP10 p.Met147Thr VAR_037428 rs121909776
11 IRF1 p.Met8Leu VAR_065134 rs121912469
12 IRF1 p.Trp11Arg VAR_065135 rs121912470
13 KRAS p.Gly12Val VAR_006840 rs121913529
14 KRAS p.Gly12Asp VAR_016026 rs121913529
15 KRAS p.Gly12Ser VAR_016028 rs121913530
16 KRAS p.Gly13Asp VAR_016029 rs112445441
17 KRAS p.Ala59Thr VAR_016030 rs121913528
18 KRAS p.Lys5Asn VAR_064849 rs104894361
19 MUTYH p.Pro402Ser VAR_026049 rs121908382

ClinVar genetic disease variations for Gastric Cancer:

6 (show top 50) (show all 186)
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.3359G> A (p.Gly1120Glu) single nucleotide variant Pathogenic rs28933379 GRCh37 Chromosome 5, 112174650: 112174650
2 APC NM_000038.5(APC): c.3359G> A (p.Gly1120Glu) single nucleotide variant Pathogenic rs28933379 GRCh38 Chromosome 5, 112838953: 112838953
3 APC NM_000038.5(APC): c.3199C> T (p.Gln1067Ter) single nucleotide variant Pathogenic rs137854571 GRCh37 Chromosome 5, 112174490: 112174490
4 APC NM_000038.5(APC): c.3199C> T (p.Gln1067Ter) single nucleotide variant Pathogenic rs137854571 GRCh38 Chromosome 5, 112838793: 112838793
5 APC NM_000038.5(APC): c.1660C> T (p.Arg554Ter) single nucleotide variant Pathogenic rs137854573 GRCh37 Chromosome 5, 112164586: 112164586
6 APC NM_000038.5(APC): c.1660C> T (p.Arg554Ter) single nucleotide variant Pathogenic rs137854573 GRCh38 Chromosome 5, 112828889: 112828889
7 APC NM_000038.5(APC): c.2805C> A (p.Tyr935Ter) single nucleotide variant Pathogenic rs137854575 GRCh37 Chromosome 5, 112174096: 112174096
8 APC NM_000038.5(APC): c.2805C> A (p.Tyr935Ter) single nucleotide variant Pathogenic rs137854575 GRCh38 Chromosome 5, 112838399: 112838399
9 MTHFR NM_005957.4(MTHFR): c.665C> T (p.Ala222Val) single nucleotide variant drug response rs1801133 GRCh37 Chromosome 1, 11856378: 11856378
10 MTHFR NM_005957.4(MTHFR): c.665C> T (p.Ala222Val) single nucleotide variant drug response rs1801133 GRCh38 Chromosome 1, 11796321: 11796321
11 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh37 Chromosome 1, 45798475: 45798475
12 MUTYH NM_001128425.1(MUTYH): c.536A> G (p.Tyr179Cys) single nucleotide variant Pathogenic rs34612342 GRCh38 Chromosome 1, 45332803: 45332803
13 MUTYH NM_001128425.1(MUTYH): c.1187G> A (p.Gly396Asp) single nucleotide variant Pathogenic/Likely pathogenic rs36053993 GRCh37 Chromosome